Mesoblast Limited
MESO
Positions held
Your positionsMESO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Mesoblast Limited is positioned in the biotechnology sector, focusing on innovative therapies that address significant unmet medical needs, which could lead to substantial market opportunities.
- The company has a market capitalization of approximately $1.77 billion, indicating a robust presence in the healthcare market.
- Analysts recommend a 'buy' with a target mean price of $37.0, suggesting significant upside potential from current levels.
- Despite its potential, Mesoblast faces challenges with a negative profit margin of -47.82%, indicating ongoing financial struggles.
- The company's operating margin is currently at -33.28%, reflecting difficulties in managing operational costs effectively.
- The stock has a 'Strong Sell' signal with a score of -24.00, driven by negative trends and technical indicators such as MACD bear and RSI≤45.
Fundamentals
| Market cap | $1.79B | Enterprise value | $1.81B | Trailing P/E | — | Forward P/E | 30.22 |
| PEG | — | Price / book | 3.14 | Beta | 0.86 | Dividend yield | 0.00% |
| Revenue growth | 3.9% | Earnings growth | — | Gross margin | 80.0% | Operating margin | -33.3% |
| Profit margin | -47.8% | ROE | -9.9% | ROA | -4.1% | Debt / equity | 0.22 |
| Current ratio | 2.44 | Free cash flow | -$51.98M | Analyst recommendation | buy | Mean target | $37.00 |
| 52w high | $21.50 | 52w low | $13.05 |
Quarterly
No data yet.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $120M | $17.2M | $5.9M | $7.5M | — |
| Op margin | -42.6% | -363.1% | -952.6% | -923.7% | — |
| Net income | -$57.5M | -$102M | -$88.0M | -$81.9M | — |
| Gross margin | 86.1% | 70.2% | 100.0% | 100.0% | — |
| Gross profit | $104M | $12.1M | $5.9M | $7.5M | — |
| Operating income | -$51.3M | -$62.4M | -$56.2M | -$69.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Top 3 Australian Healthcare Stocks To Watch In October 2026
2026-10-01 · Cochlear And 2 Australian Healthcare Stocks To Watch
2026-09-29 · 3 Australian Founder Led Stocks With Revenue Growth Up To 37%
2026-09-27 · 3 Australian Growth Stocks With Earnings Growth Up To 65%
2026-09-25 · Elite Australian Owner Operator Stocks To Own In September 2026
2026-09-24 · Sector Update: Healthcare Stocks Advance Late Afternoon
2026-09-24 · Sector Update: Healthcare Stocks Rise Thursday Afternoon
2026-09-24 · Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday
2026-09-24 · Mesoblast Gets FDA Approval for New Ryoncil Potency Assay
2026-09-24 · Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
2026-08-27 · Mesoblast Fiscal 2026 Loss Narrows, Revenue Rises
2026-08-27 · Mesoblast Reports Substantial Revenue Growth to US$120M
Price (daily)
Full chart · RSI · MACD · patterns